ライフサイエンスコーパス: soluble guanylyl cyclase

1 I)PPIX remains four coordinate when bound to soluble guanylyl cyclase.

2 Four-coordinate metalloporphyrins activate soluble guanylyl cyclase.

3 old rats do not express the beta subunit of soluble guanylyl cyclase.

4 receptors act by NO-mediated stimulation of soluble guanylyl cyclase.

5 ex, which, among other functions, stabilizes soluble guanylyl cyclase.

6 endothelial nitric oxide synthase (NOS) and soluble guanylyl cyclase.

7 quires endothelial nitric oxide synthase and soluble guanylyl cyclase.

8 d suppression of NF-kappaB and activation of soluble guanylyl cyclase.

9 ERK pathway and the subsequent activation of soluble guanylyl cyclase.

10 is via endothelial nitric-oxide synthase and soluble guanylyl cyclase.

11 by maintaining the synaptic localization of soluble guanylyl cyclase.

12 smaller extent, by the direct stimulation of soluble guanylyl cyclase.

13 show similarity to the regulatory domain of soluble guanylyl cyclases.

14 An inhibitor of soluble guanylyl cyclase, (1)H-(1,2,4)oxadiazolo(4,3-a)q

15 nor was partially blocked by an inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3, -a]q

16 Inhibition of the soluble guanylyl cyclase abolished the effect of L-argin

17 2 receptors to stimulate cGMP production via soluble guanylyl cyclase activation and absorption throu

18 vailability of NO would be too low to elicit soluble guanylyl cyclase activation in the presence of b

19 play an important role in NO generation and soluble guanylyl cyclase activation under hypoxic condit

20 With the addition of nitrite, soluble guanylyl cyclase activation was significantly hi

21 on of CO, we examined the potency of CO as a soluble guanylyl cyclase activator.

22 measured in distal human PASMCs treated with soluble guanylyl cyclase activators (nitric oxide donors

23 and cAMP-dependent mechanism for modulating soluble guanylyl cyclase activity in pituitary cells.

24 ell as beta1-sGC protein content, and impair soluble guanylyl cyclase activity.

25 (S-nitroso-N-acetyl-DL-penicillamine) and a soluble guanylyl cyclase agonist (YC-1) mimicked AMPA ef

26 nserved region (X-peptide) of the Drosophila soluble guanylyl cyclase alpha-subunit (SGCalpha).

27 GUCY1A3 encodes the alpha1 subunit of soluble guanylyl cyclase (alpha1-sGC), and CCT7 encodes

28 3-a]quinoxalin-1-one (ODQ), an inhibitor of soluble guanylyl cyclase, also blocked the effects of ni

29 Dual stimulation of soluble guanylyl cyclase and inhibition of PDE5 activiti

30 Carbon monoxide (CO) is an activator of soluble guanylyl cyclase and is implicated as a neuronal

31 es cGMP signaling, was also inhibited by the soluble guanylyl cyclase and KATP channel blockers.

32 uinea pig cochlea, by means of activation of soluble guanylyl cyclase and protein kinase G.

33 The stimulatory role of NOS is mediated by soluble guanylyl cyclase and results from a cGMP-depende

34 Nitric oxide (NO) stimulates soluble guanylyl cyclase and, thus, enhances cyclic guan

35 of Dictyostelium discoideum, a heterodimeric soluble guanylyl cyclase, and a homodimeric membrane gua

36 te transporters, nitric oxide (NO) synthase, soluble guanylyl cyclase, and ATP-sensitive potassium (K

37 esent study, we determined the role of cGMP, soluble guanylyl cyclase, and protein kinase G in the po

38 and by sodium nitroprusside, an activator of soluble guanylyl cyclase, and was potentiated by a cGMP-

39 ts is due to the lack of the beta subunit of soluble guanylyl cyclase, and we speculate that this def

40 Signaling is both soluble guanylyl cyclase- and phosphodiesterase 6-depend

41 ups in both Ni(II)- and Cu(II)-reconstituted soluble guanylyl cyclase are consistent with a substanti

42 Conventional soluble guanylyl cyclases are heterodimeric enzymes that

43 The mechanism was due to the activation of soluble guanylyl cyclase because 8-bromo-cyclic GMP acti

44 ffects of CO in this study were mediated via soluble guanylyl cyclase, because 1H-(1,2,4)oxadiazole (

45 NO targets cell proteins such as soluble guanylyl cyclase, but its detrimental effects ar

46 by N(G)-nitro-L-arginine methyl ester and of soluble guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3,-a]

47 d receptors stimulate nitric oxide-sensitive soluble guanylyl cyclase by increasing intracellular Ca(

48 Blockade of soluble guanylyl cyclase by ODQ (1H-[1,2,4] oxadiazolo[4

49 tro-L-arginine methyl ester) and blockade of soluble guanylyl cyclase (by ODQ; 1H-1,2,4-oxadiazolo[4,

50 MP analog 8-bromo-cGMP, as well as by the NO-soluble guanylyl cyclase-cGMP signaling inhibitor thromb

51 ulator BAY-41-2272 converts the CO adduct of soluble guanylyl cyclase (CO-sGC) enzyme from a low- to

52 ese data support a model where activation of soluble guanylyl cyclase correlates with the absence of

53 nisms through which NO generally acts is the soluble guanylyl cyclase-cyclic GMP (sGC-cGMP) pathway.

54 d protein modification, biologically through soluble guanylyl-cyclase-dependent modulation of the MMP

55 , we have identified a link between impaired soluble-guanylyl-cyclase-dependent nitric oxide signalli

56 global elevation of cGMP after activation of soluble guanylyl cyclase does not relax the muscle.

57 .By blocking the activity of NO synthase and soluble guanylyl cyclase enzymes after training, we prov

58 , which subsequently activates smooth muscle soluble guanylyl cyclase for vasodilation.

59 Previously characterized soluble guanylyl cyclases form alpha-beta heterodimers t

60 ht to be mediated by the action of NO on the soluble guanylyl cyclase (GC) in the smooth muscle and s

61 Soluble guanylyl cyclase (GC) is a heterodimer that is a

62 ric oxide synthase (NOS) and the NO receptor-soluble guanylyl cyclase (GC), the activation of which l

63 After stimulation with nitric oxide, soluble guanylyl cyclase generates cGMP, which induces v

64 iven pRb hyperphosphorylation occurs through soluble guanylyl cyclase/guanosine 3',5'-cyclic monophos

65 The three Drosophila atypical soluble guanylyl cyclases, Gyc-89Da, Gyc-89Db, and Gyc-8

66 contains three genes that code for atypical soluble guanylyl cyclases: Gyc-88E, Gyc-89Da, and Gyc-89

67 Recently, a separate class of soluble guanylyl cyclases has been identified that are o

68 Nitric oxide (NO) activates soluble guanylyl cyclase in smooth muscle cells to induc

69 The distribution of soluble guanylyl cyclase in the brain of the locust Schi

70 uanylyl cyclases and of 7 gcy genes encoding soluble guanylyl cyclases in the complete genome sequenc

71 imulated fluid absorption was blocked by the soluble guanylyl cyclase inhibitor 1-H-[1,2,4]oxadiazolo

72 n viable cells, which was not blocked by the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[

73 romo-cyclic GMP activated PI3 kinase and the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[

74 this lusitropic effect was attenuated by the soluble guanylyl cyclase inhibitor 1H:-[1,2,4]oxadiazolo

75 Porcine leaflets exposed to the soluble guanylyl cyclase inhibitor ODQ increased osteoca

76 ,4)oxadiazole (4,3-alpha) quinoxaline-1-one (soluble guanylyl cyclase inhibitor) completely reversed

77 e to anoxic conditions and is blocked by the soluble guanylyl cyclase inhibitor, 1H-[1,2,4]oxadiazolo

78 These effects were inhibited by LY 83583, a soluble guanylyl cyclase inhibitor, and mimicked by 8-Br

79 Furthermore, both the soluble guanylyl cyclase inhibitor, ODQ, and the specifi

80 -1-one (P<0.05 and P<0.001, respectively), a soluble guanylyl cyclase inhibitor.

81 lation and are not affected by infusion of a soluble guanylyl cyclase inhibitor.

82 ,2,4]-oxadiazolo-[4,3-a]quinoxalin-1-one) (a soluble guanylyl cyclase-inhibitor, Rp-8-(4-chlorophenyl

83 he presence of various phosphodiesterase and soluble guanylyl cyclase inhibitors, confirming that G(s

84 We have identified a novel soluble guanylyl cyclase isoform from the nervous system

85 GMP; though H(2)S does not directly activate soluble guanylyl cyclase, it maintains a tonic inhibitor

86 Inhibitors of soluble guanylyl cyclase, LY 85353 and methylene blue, a

87 by the additional presence of inhibitors of soluble guanylyl cyclase (LY83583) or protein kinase G (

88 xpression of Foxp3 in MBP-primed T cells via soluble guanylyl cyclase-mediated production of cGMP.

89 icroM 8-Bromo-cGMP), and (iii) inhibition of soluble guanylyl cyclase (ODQ (1H-[1,2,4,]oxadiazolo(4,3

90 Furthermore, inhibition of the NO target soluble guanylyl cyclase or of the cGMP effector kinase

91 Inhibitors of soluble guanylyl cyclase or PKG decreased activity of th

92 agents that release nitric oxide, stimulate soluble guanylyl cyclase, or activate cGMP-dependent pro

93 e conclude that NO production, activation of soluble guanylyl cyclase, or changes in intracellular cG

94 of NO in suppressing Foxp3(+) Tregs via the soluble guanylyl cyclase pathway.

95 rom digenic mutation carriers contained less soluble guanylyl cyclase protein and consequently displa

96 eroxynitrite scavengers or inhibitors of the soluble guanylyl cyclase/protein kinase G pathway.

97 e synthase (eNOS) by directly activating its soluble guanylyl cyclase receptor, rescued blood vessel

98 n-1-one, inhibitors of NO synthase (NOS) and soluble guanylyl cyclase, respectively, abolished tadala

99 sine 3',5'-cyclic monophosphate ([cGMP]i) by soluble guanylyl cyclase, resulting in fast onset and lo

100 , we demonstrate the effect of NO donors and soluble guanylyl cyclase (sGC) activators in differentia

101 ) derivatives have been studied as potential soluble guanylyl cyclase (sGC) activators.

102 It is shown here that soluble guanylyl cyclase (sGC) activity is required for

103 y firmly established endogenous modulator of soluble guanylyl cyclase (sGC) activity, but physiologic

104 2667 derivatives and tested their effects on soluble guanylyl cyclase (sGC) activity.

105 e isoforms (ACs 1-9), a structurally related soluble guanylyl cyclase (sGC) and a soluble AC (sAC).

106 VSMCs, expressing soluble guanylyl cyclase (sGC) and PKG-I isoforms showed

107 indicates that the functional properties of soluble guanylyl cyclase (sGC) are affected not only by

108 e have identified the alpha1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regul

109 Heme insertion is key during maturation of soluble guanylyl cyclase (sGC) because it enables sGC to

110 of recombinant nitric oxide (NO)-stimulated soluble guanylyl cyclase (SGC) by Ca2+ was demonstrated.

111 r diseases with the oxidation of the heme of soluble guanylyl cyclase (sGC) critically implicated in

112 Although soluble guanylyl cyclase (sGC) functions in an environme

113 nce that treatment with NO donors stimulates soluble guanylyl cyclase (sGC) in the MCC, and as a resu

114 9A mRNA expression closely resembles that of soluble guanylyl cyclase (sGC) in the rat brain, suggest

115 l-L-arginine (NMMA); 300 or 500 microM) or a soluble guanylyl cyclase (sGC) inhibitor (1H-[1,2,4]oxad

116 ase in cell volume that was abolished by the soluble guanylyl cyclase (sGC) inhibitor 1H-[1,2,4]oxadi

117 -nitro-L-arginine methyl ester; 30 mg/kg), a soluble guanylyl cyclase (sGC) inhibitor [1H-(1, 2, 4) o

118 nt with either a nitric oxide scavenger or a soluble guanylyl cyclase (sGC) inhibitor diminished the

119 Soluble guanylyl cyclase (sGC) is a cytosolic enzyme pro

120 Soluble guanylyl cyclase (sGC) is a heterodimeric enzyme

121 Heterodimeric alphabeta soluble guanylyl cyclase (sGC) is a recognized receptor

122 Diatomic ligand discrimination by soluble guanylyl cyclase (sGC) is paramount to cardiovas

123 Soluble guanylyl cyclase (sGC) is the major cellular rec

124 Soluble guanylyl cyclase (sGC) is the principal receptor

125 Soluble guanylyl cyclase (sGC) is the receptor for nitri

126 e of nitric oxide (NO) in the stimulation of soluble guanylyl cyclase (sGC) is well established, but

127 ts of cGMP levels in this pathway, including soluble guanylyl cyclase (sGC) itself, the NO -activated

128 of cAMP and cGMP in the above effects using soluble guanylyl cyclase (sGC) or adenylate cyclase (AC)

129 have shown that the levels of expression of soluble guanylyl cyclase (sGC) or cGMP-dependent protein

130 Soluble guanylyl cyclase (sGC) plays an important role i

131 blots for endothelial NO synthase (eNOS) and soluble guanylyl cyclase (sGC) revealed reduced eNOS exp

132 The NO receptor soluble guanylyl cyclase (sGC) was detected immunocytoch

133 the alpha(1) and beta(1) subunits of murine soluble guanylyl cyclase (sGC) were determined.

134 cular and neuronal systems via activation of soluble guanylyl cyclase (sGC), a heme-containing hetero

135 s in the brain largely through activation of soluble guanylyl cyclase (sGC), a heterodimer comprised

136 s in the brain largely through activation of soluble guanylyl cyclase (sGC), a heterodimer comprising

137 1A3, which encodes the alpha1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitr

138 They were tested for activation of soluble guanylyl cyclase (sGC), a key enzyme in the NO/c

139 Soluble guanylyl cyclase (sGC), a key protein in the NO/

140 proximately 9% contained the beta subunit of soluble guanylyl cyclase (sGC), a major target of NO.

141 of neuronal nitric oxide synthase (nNOS) and soluble guanylyl cyclase (sGC), and can be mimicked by t

142 Whereas NO and its receptor, soluble guanylyl cyclase (sGC), are emerging as key medi

143 tion of the major downstream effector of NO, soluble guanylyl cyclase (sGC), in the superficial dorsa

144 tion of the major downstream effector of NO, soluble guanylyl cyclase (sGC), is very limited.

145 tion of the major downstream effector of NO, soluble guanylyl cyclase (sGC), is very limited.

146 by localizing the expression and activity of soluble guanylyl cyclase (SGC), its principal molecular

147 ignaling through activation of its receptor, soluble guanylyl cyclase (sGC), leading to elevation of

148 NO-sensitive soluble guanylyl cyclase (sGC), one of the best characte

149 ,3-a]quinoxalin-1-one (ODQ), an inhibitor of soluble guanylyl cyclase (sGC), or Rp-8-Br-cGMP, an inhi

150 in the presence of inhibitors selective for soluble guanylyl cyclase (sGC), PKG, calmodulin, CaMKII

151 ted optic nerve, nitric oxide (NO) activates soluble guanylyl cyclase (sGC), resulting in a selective

152 h structural homology to the beta subunit of soluble guanylyl cyclase (sGC), suggesting a NO sensing

153 n yet is homologous to the central region in soluble guanylyl cyclase (sGC), the main receptor for ni

154 he molecular mechanism of desensitization of soluble guanylyl cyclase (sGC), the NO receptor, has lon

155 Soluble guanylyl cyclase (sGC), the principle "receptor"

156 We here report that soluble guanylyl cyclase (sGC), which in turn produces c

157 clinically vasoactive through stimulation of soluble guanylyl cyclase (sGC), which produces the secon

158 onducted to determine whether NO activates a soluble guanylyl cyclase (sGC)-cyclic guanosine monophos

159 ough activation of the heterodimeric enzyme, soluble guanylyl cyclase (sGC).

160 tension is attributed to reduced activity of soluble guanylyl cyclase (sGC).

161 nzyl indazole] is an allosteric activator of soluble guanylyl cyclase (sGC).

162 phosphate (cGMP) subsequent to activation of soluble guanylyl cyclase (sGC).

163 is by activating its intracellular receptor, soluble guanylyl cyclase (sGC).

164 tensity light source, to activate the enzyme soluble guanylyl cyclase (sGC).

165 to link organic nitrate to the activation of soluble guanylyl cyclase (sGC).

166 link of organic nitrate to the activation of soluble guanylyl cyclase (sGC).

167 s that investigated the regulation of the NO/soluble guanylyl cyclase (sGC)/cGMP pathway by estrogeni

168 We compared the NO/soluble guanylyl cyclase (sGC)/cGMP pathway in human gli

169 e analyzed the role of the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP/cGMP-dependent prote

170 y activates a pool of oxidized and heme-free soluble guanylyl cyclase (sGC; see the related article b

171 ked whether the classical, nitric oxide (NO)-soluble guanylyl-cyclase (sGC)-cGMP pathway could modula

172 oxide (NO) receptor (alpha1.beta1 isoform of soluble guanylyl cyclase, sGC) is not known.

173 perties of NO synthase (NOS), as well as the soluble guanylyl cyclases (sGCs), which are the best cha

174 (ODQ, 5-20 microM), a selective inhibitor of soluble guanylyl cyclase, suppressed spontaneous swimmin

175 This is the first demonstration of a soluble guanylyl cyclase that is activated in response t

176 can be achieved by activating the endogenous soluble guanylyl cyclase that produces cGMP.

177 Immunoreactivity for soluble guanylyl cyclase (the NO receptor) was at high l

178 Soluble guanylyl cyclase, the best characterized target

179 eptor-type guanylyl cyclases, the eukaryotic soluble guanylyl cyclases, the unicellular eukaryotic an

180 ion as coneurotransmitters, both stimulating soluble guanylyl cyclase to cause smooth muscle relaxati

181 h both NO and carbon monoxide (CO) stimulate soluble guanylyl cyclase to form cGMP, NO also S-nitrosy

182 o not appear to be mediated by activation of soluble guanylyl cyclase to produce cGMP, as these cells

183 through NO synthases, over interaction with soluble guanylyl cyclase, to eventual disposal as nitrit

184 Whereas soluble guanylyl cyclase was expressed at the same level

185 8-bromo-cGMP, indicating that activation of soluble guanylyl cyclase was involved.

186 on the ability of NO to access its receptor, soluble guanylyl cyclase, was explored by measuring cGMP

187 GC, indicating that particulate rather than soluble guanylyl cyclases were involved in iNOS inductio

188 M, SNP effects are probably mediated through soluble guanylyl cyclase, whereas in Sph the CNP effects

189 Although soluble guanylyl cyclase (which generates cyclic guanosi

190 ons in the brain resembling localizations of soluble guanylyl cyclase, which is activated by CO.

191 ignal via cGMP that is generated by a NO and soluble guanylyl cyclase, while bradykinin B(2) receptor

192 evel NO signals for activating its receptor, soluble guanylyl cyclase, whilst avoiding adverse effect

193 butenyl)-L-ornithine (L-VNIO, 100 microM) or soluble guanylyl cyclase with 1H-[1, 2, 4]oxadiazolo[4,

194 osis was not attenuated by the inhibition of soluble guanylyl cyclase with ODQ, nor could apoptosis b

195 sphodiesterase inhibitors, by stimulation of soluble guanylyl cyclase with YC-1 or with exogenous dib